Integrating ctDNA Into Frontline Decision-Making in EGFR-Mutant NSCLC

Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, evaluate the clinical utility of circulating tumor DNA (ctDNA) in EGFR-mutant NSCLC. They discuss whether baseline ctDNA testing should be standard, and how ctDNA positivity and clearance may serve as prognostic and predictive biomarkers. The conversation highlights how ctDNA results can support, but not solely determine, decisions around treatment intensification.